Literature DB >> 9862182

Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: results from the NHLBI Family Heart Study.

P N Hopkins1, S C Hunt, P J Schreiner, J H Eckfeldt, I B Borecki, C R Ellison, R R Williams, K D Siegmund.   

Abstract

BACKGROUND: A positive interaction between high plasma lipoprotein(a) [Lp(a)] and unfavorable plasma lipid levels has been reported to result in very high risk for premature coronary artery disease (CAD). We further examined this issue for men and women with early onset CAD. We also examined potential interactions between Lp(a) and non-lipid risk factors. METHODS AND
RESULTS: In 338 men and women with early onset CAD (most with a positive family history of early CAD) and 480 general population controls, we measured Lp(a), lipids and other risk factors. In univariate analysis, relative odds for CAD was 1.7 (P = 0.002) for plasma Lp(a) >50 mg/dl. Elevated Lp(a) level was found to interact with adjusted plasma total/high density lipoprotein (HDL) cholesterol such that when Lp(a) was over 50 mg/dl and adjusted plasma total/HDL cholesterol >5.8, relative odds for CAD were 8.0-9.6 (P<0.0001) in multiple logistic regression. Non-lipid risk factors were generally found to multiply the risk associated with Lp(a) (as predicted by logistic regression) without evidence for interaction.
CONCLUSIONS: We find evidence that Lp(a) does interact positively with adjusted plasma total/HDL cholesterol ratio. Aggressive risk factor intervention, especially for lipids, in those with elevated Lp(a) therefore appears indicated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862182     DOI: 10.1016/s0021-9150(98)00174-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Clinical implications of elevated lipoprotein(a).

Authors:  A von Eckardstein; G Assmann
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

2.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Authors:  Ruth McPherson; Jiri Frohlich; George Fodor; Jacques Genest
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

3.  Asymmetric dimethylarginine potentiates lung inflammation in a mouse model of allergic asthma.

Authors:  Elizabeth Klein; Jason Weigel; Mary C Buford; Andrij Holian; Sandra M Wells
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-10-01       Impact factor: 5.464

4.  Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS).

Authors:  Mehdi Afshar; Louise Pilote; Line Dufresne; James C Engert; George Thanassoulis
Journal:  J Am Heart Assoc       Date:  2016-04-23       Impact factor: 5.501

Review 5.  Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes.

Authors:  Enas A Enas; Arun Kuruvila; Pravien Khanna; C S Pitchumoni; Viswanathan Mohan
Journal:  Indian J Med Res       Date:  2013-10       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.